Your browser doesn't support javascript.
loading
Advances in the research and development of new drugs for chronic hepatitis B / 临床肝胆病杂志
Journal of Clinical Hepatology ; (12): 1387-1392, 2022.
Article Dans Chinois | WPRIM | ID: wpr-924719
ABSTRACT
At present, antiviral therapy for chronic hepatitis B (CHB) has a low clinical cure rate and hardly remove cccDNA. With the progress of medical science, more and more new drugs are in the stage of research and development. This article focuses on the research and development of representative drugs with relatively detailed clinical trial data. Rapid progress has been made in the new drugs such as small-interfering RNA and core protein allosteric modulators in recent years. The results of clinical trials show that it still takes some time for new drugs to enter clinical use, and multi-drug combination therapy may become the trend of treatment in the future.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Journal of Clinical Hepatology Année: 2022 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Journal of Clinical Hepatology Année: 2022 Type: Article